Journal of Neurology

, Volume 257, Issue 3, pp 359–366 | Cite as

Low sensitivity in clinical diagnoses of dementia with Lewy bodies

  • Peter T. Nelson
  • Gregory A. Jicha
  • Richard J. Kryscio
  • Erin L. Abner
  • Frederick A. Schmitt
  • Gregory Cooper
  • Li O. Xu
  • Charles D. Smith
  • William R. Markesbery
Original Communication

Abstract

The success of future neurodegenerative disease (ND) therapies depends partly on accurate antemortem diagnoses. Relatively few prior studies have been performed on large, multicenter-derived datasets to test the accuracy of final clinical ND diagnoses in relation to definitive neuropathological findings. Data were analyzed from the University of Kentucky Alzheimer’s Disease Center autopsy series and from the National Alzheimer’s Coordinating Center (NACC) registry. NACC data are derived from 31 different academic medical centers, each with strong clinical expertise and infrastructure pertaining to NDs. The final clinical diagnoses were compared systematically with subsequent neuropathology diagnoses. Among subjects meeting final inclusion criteria (N = 2,861 for NACC Registry data), the strength of the associations between clinical diagnoses and subsequent ND diagnoses was only moderate. This was particularly true in the case of dementia with Lewy bodies (DLB): the sensitivity of clinical diagnoses was quite low (32.1% for pure DLB and 12.1% for Alzheimer’s disease (AD + DLB) although specificity was over 95%. AD clinical diagnoses were more accurate (85.0% sensitivity and 51.1% specificity). The accuracy of clinical DLB diagnoses became somewhat lower over the past decade, due apparently to increased “over-calling” the diagnosis in patients with severe cognitive impairment. Furthermore, using visual hallucinations, extrapyramidal signs, and/or fluctuating cognition as part of the clinical criteria for DLB diagnosis was of minimal utility in a group (N = 237) with high prevalence of severe dementia. Our data suggest that further work is needed to refine our ability to identify specific aging-related brain disease mechanisms, especially in DLB.

Supplementary material

415_2009_5324_MOESM1_ESM.xls (28 kb)
(XLS 28 kb)
415_2009_5324_MOESM2_ESM.xls (21 kb)
(XLS 21 kb)

References

  1. 1.
    (1997) Consensus recommendations for the postmortem diagnosis of Alzheimer’s disease. The National Institute on Aging, and Reagan Institute Working Group on Diagnostic Criteria for the Neuropathological Assessment of Alzheimer’s Disease. Neurobiol Aging 18:S1-2Google Scholar
  2. 2.
    Beekly DL, Ramos EM, Lee WW, Deitrich WD, Jacka ME, Wu J, Hubbard JL, Koepsell TD, Morris JC, Kukull WA (2007) The National Alzheimer’s Coordinating Center (NACC) database: the uniform data set. Alzheimer Dis Assoc Disord 21:249–258CrossRefPubMedGoogle Scholar
  3. 3.
    Beekly DL, Ramos EM, van Belle G, Deitrich W, Clark AD, Jacka ME, Kukull WA (2004) The National Alzheimer’s Coordinating Center (NACC) database: an Alzheimer disease database. Alzheimer Dis Assoc Disord 18:270–277PubMedGoogle Scholar
  4. 4.
    Bowler JV, Munoz DG, Merskey H, Hachinski V (1998) Fallacies in the pathological confirmation of the diagnosis of Alzheimer’s disease. J Neurol Neurosurg Psychiatry 64:18–24CrossRefPubMedGoogle Scholar
  5. 5.
    Braak H, Braak E, Bohl J (1993) Staging of Alzheimer-related cortical destruction. Eur Neurol 33:403–408CrossRefPubMedGoogle Scholar
  6. 6.
    Engelborghs S, Maertens K, Nagels G, Vloeberghs E, Marien P, Symons A, Ketels V, Estercam S, Somers N, De Deyn PP (2005) Neuropsychiatric symptoms of dementia: cross-sectional analysis from a prospective, longitudinal Belgian study. Int J Geriatr Psychiatry 20:1028–1037CrossRefPubMedGoogle Scholar
  7. 7.
    Fernando MS, Ince PG (2004) Vascular pathologies and cognition in a population-based cohort of elderly people. J Neurol Sci 226:13–17CrossRefPubMedGoogle Scholar
  8. 8.
    Holtzer R, Tang MX, Devanand DP, Albert SM, Wegesin DJ, Marder K, Bell K, Albert M, Brandt J, Stern Y (2003) Psychopathological features in Alzheimer’s disease: course and relationship with cognitive status. J Am Geriatr Soc 51:953–960CrossRefPubMedGoogle Scholar
  9. 9.
    Jellinger KA (2008) A critical evaluation of current staging of alpha-synuclein pathology in Lewy body disorders. Biochim Biophys Acta 1792:730–740PubMedGoogle Scholar
  10. 10.
    Jellinger KA (2004) Lewy body-related alpha-synucleinopathy in the aged human brain. J Neural Transm 111:1219–1235CrossRefPubMedGoogle Scholar
  11. 11.
    Jellinger KA, Attems J (2008) Prevalence and impact of vascular and Alzheimer pathologies in Lewy body disease. Acta Neuropathol 115:427–436CrossRefPubMedGoogle Scholar
  12. 12.
    Jicha GA, Schmitt FA, Abner E, Nelson PT, Cooper GE, Smith CD, Markesbery WR (2008) Prodromal clinical manifestations of neuropathologically confirmed Lewy body disease. Neurobiol AgingGoogle Scholar
  13. 13.
    Kraybill ML, Larson EB, Tsuang DW, Teri L, McCormick WC, Bowen JD, Kukull WA, Leverenz JB, Cherrier MM (2005) Cognitive differences in dementia patients with autopsy-verified AD, Lewy body pathology, or both. Neurology 64:2069–2073CrossRefPubMedGoogle Scholar
  14. 14.
    Lopez OL, Hamilton RL, Becker JT, Wisniewski S, Kaufer DI, DeKosky ST (2000) Severity of cognitive impairment and the clinical diagnosis of AD with Lewy bodies. Neurology 54:1780–1787PubMedGoogle Scholar
  15. 15.
    Luis CA, Barker WW, Gajaraj K, Harwood D, Petersen R, Kashuba A, Waters C, Jimison P, Pearl G, Petito C, Dickson D, Duara R (1999) Sensitivity and specificity of three clinical criteria for dementia with Lewy bodies in an autopsy-verified sample. Int J Geriatr Psychiatry 14:526–533CrossRefPubMedGoogle Scholar
  16. 16.
    McKeith I, Mintzer J, Aarsland D, Burn D, Chiu H, Cohen-Mansfield J, Dickson D, Dubois B, Duda JE, Feldman H, Gauthier S, Halliday G, Lawlor B, Lippa C, Lopez OL, Carlos Machado J, O’Brien J, Playfer J, Reid W (2004) Dementia with Lewy bodies. Lancet Neurol 3:19–28CrossRefPubMedGoogle Scholar
  17. 17.
    McKeith IG, Dickson DW, Lowe J, Emre M, O’Brien JT, Feldman H, Cummings J, Duda JE, Lippa C, Perry EK, Aarsland D, Arai H, Ballard CG, Boeve B, Burn DJ, Costa D, Del Ser T, Dubois B, Galasko D, Gauthier S, Goetz CG, Gomez-Tortosa E, Halliday G, Hansen LA, Hardy J, Iwatsubo T, Kalaria RN, Kaufer D, Kenny RA, Korczyn A, Kosaka K, Lee VM, Lees A, Litvan I, Londos E, Lopez OL, Minoshima S, Mizuno Y, Molina JA, Mukaetova-Ladinska EB, Pasquier F, Perry RH, Schulz JB, Trojanowski JQ, Yamada M (2005) Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology 65:1863–1872CrossRefPubMedGoogle Scholar
  18. 18.
    McKeith IG, Galasko D, Kosaka K, Perry EK, Dickson DW, Hansen LA, Salmon DP, Lowe J, Mirra SS, Byrne EJ, Lennox G, Quinn NP, Edwardson JA, Ince PG, Bergeron C, Burns A, Miller BL, Lovestone S, Collerton D, Jansen EN, Ballard C, de Vos RA, Wilcock GK, Jellinger KA, Perry RH (1996) Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the Consortium on DLB International Workshop. Neurology 47:1113–1124PubMedGoogle Scholar
  19. 19.
    Merdes AR, Hansen LA, Jeste DV, Galasko D, Hofstetter CR, Ho GJ, Thal LJ, Corey-Bloom J (2003) Influence of Alzheimer pathology on clinical diagnostic accuracy in dementia with Lewy bodies. Neurology 60:1586–1590PubMedGoogle Scholar
  20. 20.
    Mirra SS (1997) The CERAD neuropathology protocol and consensus recommendations for the postmortem diagnosis of Alzheimer’s disease: a commentary. Neurobiol Aging 18:S91–S94CrossRefPubMedGoogle Scholar
  21. 21.
    Mok W, Chow TW, Zheng L, Mack WJ, Miller C (2004) Clinicopathological concordance of dementia diagnoses by community versus tertiary care clinicians. Am J Alzheimer’s Dis Other Demen 19:161–165CrossRefGoogle Scholar
  22. 22.
    Nelson PT, Abner EL, Schmitt FA, Kryscio RJ, Jicha GA, Smith CD, Davis D, Poduska JW, Patel E, Mendiondo MM, Markesbery WR (2008) Modeling the association between 43 different clinical and pathological variables and the severity of cognitive impairment in a large autopsy cohort of elderly persons. Brain Pathol (in press)Google Scholar
  23. 23.
    Nelson PT, Braak H, Markesbery WR (2009) Neuropathology and cognitive impairment in Alzheimer disease: a complex but coherent relationship. J Neuropathol Exp Neuro 68:1–14CrossRefGoogle Scholar
  24. 24.
    Nelson PT, Jicha GA, Schmitt FA, Liu H, Davis DG, Mendiondo MS, Abner EL, Markesbery WR (2007) Clinicopathologic correlations in a large Alzheimer disease center autopsy cohort: neuritic plaques and neurofibrillary tangles “do count” when staging disease severity. J Neuropathol Exp Neurol 66:1136–1146CrossRefPubMedGoogle Scholar
  25. 25.
    Nelson PT, Kryscio RJ, Abner EL, Schmitt FA, Jicha GA, Mendiondo MS, Cooper G, Smith CB, Markesbery WR (2009) Acetylcholinesterase inhibitor treatment is associated with relatively slow cognitive decline in patients with Alzheimer’s disease and AD + DLB. J Alzheimers Dis 16:29–34PubMedGoogle Scholar
  26. 26.
    Olichney JM, Galasko D, Salmon DP, Hofstetter CR, Hansen LA, Katzman R, Thal LJ (1998) Cognitive decline is faster in Lewy body variant than in Alzheimer’s disease. Neurology 51:351–357PubMedGoogle Scholar
  27. 27.
    Parkkinen L, Kauppinen T, Pirttila T, Autere JM, Alafuzoff I (2005) Alpha-synuclein pathology does not predict extrapyramidal symptoms or dementia. Ann Neurol 57:82–91CrossRefPubMedGoogle Scholar
  28. 28.
    Parkkinen L, Pirttila T, Alafuzoff I (2008) Applicability of current staging/categorization of alpha-synuclein pathology and their clinical relevance. Acta Neuropathol 115:399–407CrossRefPubMedGoogle Scholar
  29. 29.
    Parkkinen L, Pirttila T, Tervahauta M, Alafuzoff I (2005) Widespread and abundant alpha-synuclein pathology in a neurologically unimpaired subject. Neuropathology 25:304–314CrossRefPubMedGoogle Scholar
  30. 30.
    Parkkinen L, Soininen H, Alafuzoff I (2003) Regional distribution of alpha-synuclein pathology in unimpaired aging and Alzheimer disease. J Neuropathol Exp Neurol 62:363–367PubMedGoogle Scholar
  31. 31.
    Parkkinen L, Soininen H, Laakso M, Alafuzoff I (2001) Alpha-synuclein pathology is highly dependent on the case selection. Neuropathol Appl Neurobiol 27:314–325CrossRefPubMedGoogle Scholar
  32. 32.
    Pearl GS (1997) Diagnosis of Alzheimer’s disease in a community hospital-based brain bank program. South Med J 90:720–722CrossRefPubMedGoogle Scholar
  33. 33.
    Rosenberg CK, Pericak-Vance MA, Saunders AM, Gilbert JR, Gaskell PC, Hulette CM (2000) Lewy body and Alzheimer pathology in a family with the amyloid-beta precursor protein APP717 gene mutation. Acta Neuropathol 100:145–152CrossRefPubMedGoogle Scholar
  34. 34.
    Schneider JA, Wilson RS, Bienias JL, Evans DA, Bennett DA (2004) Cerebral infarctions and the likelihood of dementia from Alzheimer disease pathology. Neurology 62:1148–1155PubMedGoogle Scholar
  35. 35.
    Stavitsky K, Brickman AM, Scarmeas N, Torgan RL, Tang MX, Albert M, Brandt J, Blacker D, Stern Y (2006) The progression of cognition, psychiatric symptoms, and functional abilities in dementia with Lewy bodies and Alzheimer disease. Arch Neurol 63:1450–1456CrossRefPubMedGoogle Scholar
  36. 36.
    Trembath Y, Rosenberg C, Ervin JF, Schmechel DE, Gaskell P, Pericak-Vance M, Vance J, Hulette CM (2003) Lewy body pathology is a frequent co-pathology in familial Alzheimer’s disease. Acta Neuropathol 105:484–488PubMedGoogle Scholar
  37. 37.
    Tsuang D, Simpson K, Larson EB, Peskind E, Kukull W, Bowen JB, McCormick W, Teri L, Montine T, Thompson ML, Leverenz JB (2006) Predicting Lewy body pathology in a community-based sample with clinical diagnosis of Alzheimer’s disease. J Geriatr Psychiatry Neurol 19:195–201CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag 2009

Authors and Affiliations

  • Peter T. Nelson
    • 1
    • 4
  • Gregory A. Jicha
    • 2
    • 4
  • Richard J. Kryscio
    • 3
    • 4
  • Erin L. Abner
    • 4
  • Frederick A. Schmitt
    • 2
    • 4
  • Gregory Cooper
    • 2
  • Li O. Xu
    • 3
  • Charles D. Smith
    • 2
    • 4
  • William R. Markesbery
    • 1
    • 2
    • 4
  1. 1.Division of Neuropathology, Department of PathologyUniversity of Kentucky Medical Center and Sanders-Brown Center on Aging, University of KentuckyLexingtonUSA
  2. 2.Department of NeurologyUniversity of KentuckyLexingtonUSA
  3. 3.Department of StatisticsUniversity of KentuckyLexingtonUSA
  4. 4.Sanders-Brown Center on AgingUniversity of KentuckyLexingtonUSA

Personalised recommendations